3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Paclitaxel
3
Ipilimumab
3
Cyclophosphamide
3
Carboplatin
3
padeliporfin
2
atezolizumab
2
anlotinib
2
Riluzole
2
Gemcitabine
2
vinflunine
1
sipuleucel-T
1
relatlimab
1
palbociclib
1
olaparib
1
niraparib
1
motexafin gadolinium
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
cabozantinib
1
Therapeutics
1
Suspensions
1
Surveys and Questionnaires
1
Sunitinib
1
Specimen Handling
1
Powders
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urogenital Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled